Overview

Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
It is the aim of this clinical study to evaluate the skeletal-related event rate under therapy with zoledronic acid in patients with renal cell cancer having at least one cancer-related bone lesion.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Diphosphonates
Zoledronic Acid